Quality of life in the trastuzumab for gastric cancer trial.

Abstract

BACKGROUND:

The Trastuzumab for Gastric Cancer phase III trial demonstrated that combining trastuzumab with chemotherapy significantly improved overall survival compared with chemotherapy alone in HER2-positive advanced gastric or gastroesophageal junction cancer. We report health-related quality of life (HRQoL) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from this trial.

PATIENTS AND METHODS:

Patients were randomized to receive six cycles of chemotherapy given every 3 weeks (capecitabine or fluorouracil, plus cisplatin) either alone or combined with administration of trastuzumab every 3 weeks until disease progression. At each clinical visit, HRQoL was assessed using two European Organization for Research and Treatment of Cancer quality of life questionnaires, QLQ-C30 and QLQ-STO22. Q-TWiST methodology was applied retrospectively using the clinical data and utility coefficients.

RESULTS:

Trastuzumab plus chemotherapy prolonged time to 10% definitive deterioration in all QLQ-C30 and QLQ-STO22 scores, including QLQ-C30 global health status versus chemotherapy alone, from 6.4 months to 10.2 months. In addition, trastuzumab plus chemotherapy extended Q-TWiST by 2.42 months compared with chemotherapy alone.

CONCLUSION:

Compared with chemotherapy alone, trastuzumab plus chemotherapy prolongs time to deterioration of HRQoL and increases quality-adjusted survival in patients with HER2-positive gastric or gastroesophageal junction cancer.

• Authors: Taroh Satoh, Yung-Jue Bang, Evgeny A Gotovkin, Yasuo Hamamoto, Yoon-Koo Kang, Vladimir M Moiseyenko, Atsushi Ohtsu, Eric Van Cutsem, Nedal Al-Sakaff, Alexa Urspruch, Julie Hill, Harald A Weber, Hyun-Cheol Chung, ToGA Trial Investigators
• Journal: The oncologist (Oncologist) Vol. 19 Issue 7 Pg. 712-9 (Jul 2014) ISSN: 1549-490X [Electronic] England
• PMID: 24951609 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: ©AlphaMed Press.

Chemical References

• Antibodies, Monoclonal, Humanized
• Deoxycytidine
• Capecitabine
• ERBB2 protein, human
• Receptor, ErbB-2
• Trastuzumab
• Cisplatin
• Fluorouracil

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Capecitabine
• Cisplatin (administration & dosage, adverse effects)
• Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives)
• Fluorouracil (administration & dosage, adverse effects, analogs & derivatives)
• Humans
• Quality of Life
• Receptor, ErbB-2 (metabolism)
• Stomach Neoplasms (drug therapy, enzymology)
• Surveys and Questionnaires
• Trastuzumab